The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.

Publication date: Feb 18, 2025

Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that displays great variability in clinical phenotype. Many factors have been described to be correlated with its severity, and microbiota could play a key role in the infection, progression, and outcome of the disease. SARS-CoV-2 infection has been associated with nasopharyngeal and gut dysbiosis and higher abundance of opportunistic pathogens. To identify new prognostic markers for the disease, a multicentre prospective observational cohort study was carried out in COVID-19 patients divided into three cohorts based on symptomatology: mild (n = 24), moderate (n = 51), and severe/critical (n = 31). Faecal and nasopharyngeal samples were taken, and the microbiota was analysed. Linear discriminant analysis identified Mycoplasma salivarium, Prevotella dentalis, and Haemophilus parainfluenzae as biomarkers of severe COVID-19 in nasopharyngeal microbiota, while Prevotella bivia and Prevotella timonensis were defined in faecal microbiota. Additionally, a connection between faecal and nasopharyngeal microbiota was identified, with a significant ratio between P. timonensis (faeces) and P. dentalis and M. salivarium (nasopharyngeal) abundances found in critically ill patients. This ratio could serve as a novel prognostic tool for identifying severe COVID-19 cases.

Open Access PDF

Concepts Keywords
Biomarkers Adult
Coronavirus Aged
Illness COVID-19
Mild Dysbiosis
Salivarium Feces
Female
Gastrointestinal Microbiome
human
Humans
immunology
infectious disease
inflammation
Male
microbiology
microbiome
Microbiota
Middle Aged
nasopharyngeal
Nasopharynx
Prevotella
Prognosis
Prospective Studies
SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease IDO role
disease MESH infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH dysbiosis
disease MESH critically ill
disease MESH Long Covid
drug DRUGBANK Coenzyme M
disease MESH Inflammation
disease IDO symptom
disease MESH respiratory failure
disease MESH death
disease IDO blood
disease IDO pathogen
drug DRUGBANK Serine
disease IDO bacteria
disease MESH secondary infections
disease MESH morbidity
disease MESH viral infection
disease MESH infectious disease
pathway REACTOME Infectious disease

Original Article

(Visited 1 times, 1 visits today)